Full-Time
Clinical-stage biotech antibodies for IBD
$275k - $290k/yr
Remote in USA
Remote
| , |
Spyre Therapeutics develops long-acting antibody therapies for inflammatory bowel disease, including anti-α4β7 and anti-TL1A programs for ulcerative colitis and Crohn’s disease. These antibodies target immune pathways to reduce gut inflammation, aiming for durable effects, easier dosing, and potential for combination therapies. The company shifted from engineered enzymes for rare metabolic diseases to immunology-focused biologics, deprioritizing pegzilarginase and maintaining it only as historical activity. Its goal is to discover, develop, and potentially commercialize durable antibodies that address large, underserved GI patient populations.
Company Size
11-50
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2023
Help us improve and share your feedback! Did you find this helpful?
People at Spyre Therapeutics who can refer or advise you
Unlimited Paid Time Off
Remote Work Options
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Equity
Health Savings Account/Flexible Spending Account
Wellness Program
Professional Development Budget
Conference Attendance Budget
Stock Options
Company Equity
Professional Development Budget
Remote Work Options
WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory
Spyre Therapeutics has launched a $300 million underwritten public offering of common stock. The company may grant underwriters the option to purchase an additional $45 million in shares within 30 days. All shares in the offering will be sold directly by the company.
Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock for approximately $740,000 on 1 April 2026, according to an SEC filing. The transaction, executed under a Rule 10b5-1 trading plan adopted in June, represented 2.33% of his direct holdings and follows a roughly 300% share price increase over the past year. The sale appears to be routine profit-taking rather than a change in outlook. Spyre recently accelerated a key clinical catalyst, with its SKYWAY rheumatoid arthritis sub-study now expected to deliver topline data in Q3 2026 after completing enrolment ahead of schedule. Additional readouts across psoriatic arthritis and axial spondyloarthritis remain on track for Q4. The biotechnology company, valued at $4 billion, develops monoclonal antibody therapeutics targeting inflammatory bowel disease.
Apr. 7, 2016- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the pricing of its initial public offering of 5,000,000 shares
Spyre Therapeutics has raised investor attention following a 127% one-year total return, despite a recent 2.5% one-day decline. The stock trades at $41.25, approximately 47% below the average analyst price target of $60.79. The company's price-to-book ratio of 5.8x sits well above the US biotechs industry average of 2.5x, though below a peer group average of 9.4x. This suggests the market is pricing in significant premium for its inflammatory bowel disease and rheumatic conditions pipeline. Spyre Therapeutics remains loss-making, reporting net losses of $126.5 million and generating less than $1 million in revenue. The elevated valuation relative to its balance sheet reflects investor expectations for future growth, though clinical programme outcomes remain uncertain.